The has mandated manufacturers to improve traceability, which is essential for ensuring that medicines reach patients safely. 麻豆原创 Information Collaboration Hub for Life Sciences is designed to help meet these demands by streamlining the tracking process. However, as the network of users has grown, support challenges have surfaced. To address these issues, 麻豆原创 introduced Built-In Support into the hub to help provide direct, seamless assistance to life sciences companies and their partners.

I had the opportunity to interview Tarun Luthra, head of Support 鈥� Industries & CX, and Andreas Krummlauf, vice president and head of Product Management Life Sciences, Health and Ecosystem, about the project鈥檚 impact. Here’s how Built-In Support is helping to enhance operational efficiency for network users in the life sciences industry.

Q: How did this project come about?

Krummlauf: , manufacturers of medicine needed to develop the ability to uniquely identify every pack of medicine they sell in those countries. This is to avoid counterfeiting in the legitimate supply chain. To support this requirement, 麻豆原创’s serialization portfolio was initiated in 2015 with the 麻豆原创 Advanced Track and Trace for Pharmaceuticals application, a corporate serialization repository.

麻豆原创 Information Collaboration Hub for Life Sciences started in 2016 with a focused goal: to manage traceability and serialization data exchange for our customers and a couple of hundred of their business partners. In 2021, the hub won the Hasso Plattner Founders鈥� Award.

As the network expanded to tens of thousands of partners, a key limitation emerged: we did not have a simple way for business partners, acting as network end users, to directly interact with 麻豆原创 support in case of critical issues, even without having a support contract with 麻豆原创 in place.

Q: What support challenges were network end users facing?

Luthra: The challenge arose from supporting an increasing number of network end users that were not direct 麻豆原创 customers. Without access to 麻豆原创鈥檚 support system, the network end users had to rely on their customers to resolve issues, adding unnecessary steps and risked communication gaps. This presented an opportunity to implement Built-In Support to support our customers鈥� business partners as network end users when they use 麻豆原创 Information Collaboration Hub for Life Sciences.

Q: How does Built-In Support make a difference for network end users?

Luthra: We are now providing network end users with a direct entry point from within 麻豆原创 Information Collaboration Hub for Life Sciences, enabling them to easily contact the support team. Built-In Support is seamlessly integrated into the hub. The network end user can find help by searching 麻豆原创 Knowledge Base Articles or submitting a case.

Krummlauf: This streamlined process can enhance the support experience and helps ensure users can quickly find the help they need. Network end users can now resolve issues independently or submit a case without involving customers in the resolution process. This improvement leads to faster response times. Users can efficiently search for relevant product information and potentially resolve issues on their own. This autonomy helps enhance the overall support experience and empowers users to find solutions quickly and effectively.

Built-In Support Enhances User Experience and Support Efficiency

In conclusion, marks a significant advancement in enhancing user experience and support efficiency. When network end users are empowered to directly access support resources and resolve issues independently, we not only help to streamline the support process but also reinforce 麻豆原创’s commitment to improving lives through better life sciences solutions. As regulatory demands evolve, our innovative approaches will continue to drive progress and collaboration in the life sciences sector. For more insights, stay connected with 麻豆原创’s ongoing developments.

When we started to talk, Andreas Heckmann, executive vice president and head of Customer Solution Support & Innovation at 麻豆原创, stated, 鈥淎lthough it was one of the most challenging years in my professional history, it was still a year filled with opportunities. We are seeing traction in the transformation of customer support I described 11 months ago, and we delivered a great amount of product innovations to our customers.鈥�

In this interview, Heckmann gives insight into how the transformation is continuing.

Q: How has 2022 been going for you in the transformation?

A: I鈥檓 proud of the notable, award-winning product releases that are directly relevant to supporting economic needs and helping with sustainability. Take, for example, the solution. We鈥檙e enabling agribusinesses to tap into their vast source of farming data by leveraging data science and machine learning. This farming intelligence helps them leverage processes and services to better forecast and increase farming yields and quality. It will also help them use the right balance of water resources and help keep fertilizer and crop protection to a minimum. This will help agribusinesses play their part in becoming more sustainable and efficient.

Let me also point out the Hasso Plattner Founders鈥� Award-winning . It鈥檚 helping prevent pharmaceutical drug counterfeiting by enabling traceability and verification of products. With an estimated 50% or more of drugs in Africa being counterfeit, this product is definitely helping businesses to protect their intellectual property and, more importantly, people鈥檚 health and lives.

Another exciting sustainability-focused app release this year is the . In this project, we developed a solution extension to help neutralize carbon emissions. Our customers can access data collected from business travel and consider ways to watch their carbon footprint.

All of these solutions make me proud of our Customer Solution Support & Innovation organization and underscores the many ways we have our customers鈥� goals and priorities front of mind.

With 麻豆原创 Cloud ALM being available for a while now, how do you see it being taken up?

is the strategic platform to help customers manage their entire application lifecycle, both on premise and in the cloud. We will close out this year seeing quite an amazing uptake and increasingly more customers using the solution to help implement and operate their cloud and hybrid environments. There鈥檚 a big uptake on 麻豆原创 Cloud ALM, with functions being used more intensely for managing project teams and business processes. And it鈥檚 also getting third-party products integrated to give customers even more access to content such as guidance, tools, and checklists for their implementation projects and operations.

What progress are you making around Real-Time Support during this transformation?

We鈥檙e seeing momentum in continuously transforming the support experience for customers towards a more personalized and preventative experience. This could be when they search for a support answer in or , or when they report an issue. At the beginning of this year, we received a for the innovative way we鈥檙e capturing our customer problems in a structured and guided fashion. It鈥檚 what we call support assistant. This assistant guides customers through the process of logging an incident. Machine learning functionality suggests answers from our knowledge repositories along the way. Often the answer is found in the first bunch of suggestions and no incident needs to be created.

If no answer can be provided instantaneously, the incident information collected is packaged for a support engineer to process further during a or a scheduled appointment. We found that real-time interactions get completed on average within 30 minutes and two of every three issues are solved in the first chat. And these interactions support nine different languages, allowing for multi-language dialogues in real time. For either way the customer decides to go, the support assistant and help customers get their issues resolved much more quickly and efficiently.

Now imagine, we鈥檙e already working on the next generation of the entire support experience for customers to look forward to. With Built-In Support, we鈥檙e making significant progress as the tool for continuous two-way dialogue with customers. It鈥檚 our goal to proactively notify customers about critical issues or relevant new features and to take care of any potential problem before a customer becomes aware of it. We鈥檙e also eagerly awaiting the go-live of our new customer facing portal, 麻豆原创 for Me, with its completely redesigned user experience.

麻豆原创 is getting into customer-centric observability. What does this mean?

Customers trust us with their critical business processes. Service availability is the foundation of that trust and naturally a prime topic for us. We see it as a prerequisite for customer success. A focus of our transformation is to become more predictive and proactive. It鈥檚 what we鈥檙e calling customer-centric observability. This is a methodology that focuses on observing real user experience and outcomes to get advanced warnings ahead of customer-reported incidents and to quickly react upon them. By monitoring 1.5 billion system actions daily, we鈥檙e proactively watching for potential issues and preventing them from happening.

What can we expect for 2023?

Personally, I’m excited to see the launch of the bi-directional dialogue in Built-In Support and 麻豆原创 for Me. This means customers can look forward to getting an even better support experience in 2023. In addition, they should expect to get significantly improved results and optimized recommendations when searching for solutions or creating incident tickets for support. Plus, there will be more times when potential problems are resolved without customers even knowing any problems existed. While we will certainly not be done next year, given all we鈥檝e planned for our customers, I鈥檓 confident that we鈥檒l already begin reaping the harvest.

Follow Andreas Heckmann on and .
Regina Postman is part of Customer Solution Support & Innovation Communications at 麻豆原创.

Increasing regulations are also sparking digital innovation across life sciences. For example, organizations are required to share updated supply chain data with trusted partners for compliance with the final phased-in regulations of the . Initially passed in 2013, the latest batch of requirements from this act will require pharmacies, wholesalers, and manufacturers to track and report drug shipments for legitimacy between authorized trading partners. That鈥檚 where Spherity Credentialing Service CARO comes in, an app that provides updated information proving a dispenser鈥檚 trading partner status.

鈥淲hen a pharmacist in a tiny dispensary in North Dakota has suspicions about a received drug shipment, they send a verification request to a global pharmaceutical manufacturer that has numerous wholesalers in between them and the pharmacy,鈥� said Dr. Oliver Nuernberg, chief product owner of Life Sciences at 麻豆原创. 鈥淎utomating the credentialing process builds transparency and trust between indirect partners, immediately surfacing the pharmacy鈥檚 credentials as an authorized trading partner. This saves time and costs with greater information accuracy and fewer delays, strengthening an organization鈥檚 ability to meet DSCSA regulations.鈥�

Available on , Spherity Credentialing Service CARO is integrated with聽, a cloud-based network solution that helps organizations comply with other provisions of the U.S.聽DSCSA. For example, drug traceability is another U.S. DSCSA mandate. Pharmaceutical manufacturers can also use the information hub to help law enforcement trace drug shipments by serial numbers, supporting audits that help keep counterfeit medications out of the supply chain.

Intelligent Automation Strengthens Health of Drug Supply Chain

Spherity functions as a digitally encrypted wallet that captures and stores a dispenser鈥檚, or any other trading partner鈥檚, verified identity data, including address, notarized documents such as articles of incorporation, as well as updated U.S. state and DEA license information. By digitizing previously manual data collection and distribution tasks between systems, the app eliminates historical time lags that often resulted in outdated information.

鈥淚n the past, information about trading partner status was manually imported on a monthly basis from spreadsheets provided by third parties. An order might come from a wholesaler or dispenser whose license expired or was revoked weeks or even months ago,鈥� said Nuernberg. 鈥淓lectronic credentialing surfaces accurate information much faster, helping organizations automatically prove compliance with regulations, including license type as required to dispense various drugs.鈥�

Once a pharmacy鈥檚 identity is verified in their digital wallet, pharmaceutical companies would also be informed on an ongoing basis if the state or federal agency didn鈥檛 renew that license or revoked it for any reason.

Verified Partner Identity for Supply Chain Safety

Verifying a dispenser鈥檚 identity isn鈥檛 as easy as it sounds. Drug supply chains are complex, involving manufacturers, wholesale distributors, re-packagers, and logistics companies long before the goods reach pharmacies for dispensing. Having an app that automatically verifies a dispenser鈥檚 identity in real or near real time is designed to support regulatory compliance and help make drug supply chains more secure. Anticipating the 2023 regulations, some global pharmaceutical manufacturers and wholesalers have been testing the app with measurable results.

鈥淯sing the app, organizations have told us that they can securely and more easily verify trading partners and generate audit-ready records,鈥� said Georg J眉rgens, manager of Industry Solutions at Spherity. 鈥淲ith electronic interactions, they can trust that a trading partner is legitimate because due diligence has been conducted that proves identity. The app is easy to get up and running and has already increased efficiencies.鈥�

J眉rgens added that the app鈥檚 interoperability with different systems is designed to help meet regulatory mandates around electronic data sharing, easing collaboration between trusted partners along the clinical supply chain.

Digitalized Business Innovation

Eliminating counterfeit drugs in the legitimate supply chain is just the beginning of what鈥檚 possible in a fully digitalized life sciences supply chain. Pharmaceutical companies will be able to bring in and ramp up new, trusted suppliers faster. Intelligence will only grow with greater automation for business and patient value.

Follow me @smgaler.

Industry innovation has been a fascinating topic over the last few years. It鈥檚 impossible to ignore how companies create new offerings and experiences that dramatically shift how an industry 鈥� or in some cases, multiple industries 鈥� operates and how people live. Such groundbreaking changes are usually built with an appreciation of existing data and technologies and through a desire to do things better in terms of product safety, supply chain optimization, and business finances.

I鈥檝e been very fortunate to experience the power of such industry innovation through the Customer Innovation & Maintenance team as part of the Customer Solution Support & Innovation organization at 麻豆原创. For years, we have worked with various organizations to navigate existing crises, address emerging challenges, and deliver new opportunities for the world. In this article, I will discuss three of our latest projects.

Saving People鈥檚 Lives by Reducing Counterfeit Drugs

One prime example of our efforts is tackling a global menace that impacts the entire world: counterfeit pharmaceuticals. Many falsified or substandard medicines contain dangerous ingredients, such as heavy metals, highway paint, and rat poison, that worsen people鈥檚 health conditions and create new diseases. As a result, the World Health Organization (WHO) estimates that more than yearly from these snake oil cures.

For years, governments have initiated legislation and regulations to criminalize and control the production and distribution of counterfeit drugs. However, my team discovered that the lack of a rigorous, universal network makes it difficult to curtail the problem often hidden within complex supply chains and sophisticated packaging.

Based on input from 麻豆原创 customers in the life sciences industry and working with 麻豆原创 industry experts on this international challenge, we developed . The industry network hub enables pharmaceutical firms to share product information for traceability and verification across the supply network and with government regulators. Running on and leveraging 麻豆原创 Blockchain Business Services, it is the first public-cloud, industry-specific business network used by more than 45 pharmaceutical firms, over 1,500 trading partners, and 80% of COVID-19 vaccine manufacturers.

But our contribution to the fight against counterfeit drugs is far from over. We are working toward adding aid workers from organizations 鈥� such as the Red Cross and Doctors Without Borders 鈥� to the hub so they can verify critical medicines and vaccines on the fly in low- to middle-income countries. This innovation is accomplished by integrating the hub into the application.

Accelerating the Development of Lifesaving Therapies

Another barrier to delivering large quantities of medical therapies quickly, efficiently, and safely is the structure of the traditional clinical supply chain. During the COVID-19 pandemic, supply chain resilience was highlighted as a critical requirement for providing lifesaving vaccines, prophylactics, and therapies created through industry-wide collaboration and a patient-centric focus.

To accelerate clinical R&D and time to value, my team worked with Roche, Tenthpin, and more than 25 additional customers and vendors connected to the pharmaceutical sector. Together, we reimagined clinical supply operations and brought to life a digital transformation of the entire life sciences ecosystem by developing the solution.

This next-generation cloud solution enables faster clinical supply cycle times, fewer inventory overages, and better-informed decision-making by providing accurate insights into forecasted demand and clinical site stock levels. It is also a milestone in the industry鈥檚 adoption of the cloud, facilitating end-to-end process operations and visibility to plan, source, manufacture, distribute, and reconcile supplies for clinical R&D. In addition, the solution helps address the blinding and randomization needs of clinical trials during the manufacturing, packaging, labeling, and shipment of clinical supplies to hospitals and clinics.

Meeting Financing Needs to Boost Growth

In addition to counterfeit drugs and the need for resilience, supply chain volatility and turbulence is providing the impetus for innovation. This reality is prompting capital investments including end-to-end due diligence and product tracing services; machines and plant setups that improve environmental impacts; and networks for finding, vetting, and onboarding new suppliers quickly.

Incorporating all these innovations into business operations 鈥� regardless of ecosystem size and geographic reach 鈥� requires money that many companies may not have immediately on hand. But to meet those finance needs, businesses and banks need to connect with each other smoothly, quickly, and securely without introducing more work and complexity to finance and treasury processes.

By delivering the solution, we play a key role in increasing the reliability of relationships between companies and their banks. Built on top of 麻豆原创 Business Technology Platform, the solution creates a multi-bank, digital channel between each party鈥檚 enterprise resource planning (ERP) systems to embed Electronic Banking Internet Communication Standard (EBICS) and SWIFT connectivity into the remote data transfer of payment transactions.

In return, treasury operations can be refined and simplified by updating payment status and cash positions in real time across business and bank ERP systems. 麻豆原创 Multi-Bank Connectivity can automate manual, error-prone steps associated with the execution and reconciliation of payments, order-to-cash applications, and order entry documents 鈥� helping to increase control, efficiency, and transparency.

Helping the World Run Better 鈥� One Innovation at a Time

The news headlines running across our screens every day prove that industry innovation is far from done. Unfortunately, no person, organization, or business carries the ultimate wisdom to solve every problem single-handedly. But if industry practitioners, business and technology experts, thought leaders, and inspired problem-solvers collaborate toward a common goal, a better future can be possible for everyone.

It is this vision that guides my leadership of Customer Solution Support & Innovation. My team of experts continuously looks for opportunities to do better for our customers, business, and global neighbors. And with the feedback and knowledge shared during every interaction, we look forward to working side by side with our customers and partners to provide the digital capabilities they need to make the world a better place 鈥� today and in the future.

Andreas Heckmann is executive vice president of Product Engineering and head of Customer Solution Support and Innovation at 麻豆原创. Follow him on and .